U.S. Markets closed

Oramed Pharmaceuticals Inc. (ORMP)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.2600-0.1900 (-4.27%)
At close: 4:00PM EST

4.3000 +0.04 (0.94%)
After hours: 7:53PM EST

Oramed Pharmaceuticals Inc.

1185 Avenue of the Americas
3rd Floor
New York, NY 10036
United States
844 967 2633
http://www.oramed.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Nadav KidronPres, CEO & Exec. Director1.15MN/A1974
Mr. Avraham GabayCFO, Treasurer & Sec.202.17kN/A1985
Dr. Miriam KidronChief Scientific Officer & Director405.04kN/A1940
Mr. Joshua HexterChief Operating & Bus. OfficerN/AN/A1970
Dr. Roy Eldor M.D., Ph.D.Chief Medical Advisor & Member of the Scientific Advisory BoardN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.

Corporate Governance

Oramed Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.